デフォルト表紙
市場調査レポート
商品コード
1466634

注射剤市場:分子タイプ、薬剤クラス、注射経路、用途別-2024~2030年の世界予測

Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 199 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
注射剤市場:分子タイプ、薬剤クラス、注射経路、用途別-2024~2030年の世界予測
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

注射剤市場規模は、2023年に5,633億米ドルと推定され、2024年には6,170億4,000万米ドルに達し、CAGR 9.86%で2030年には1兆885億5,000万米ドルに達すると予測されます。

注射剤市場は、静脈内(IV)、筋肉内(IM)、皮下(SC)注射ルートで投与される医薬品と治療法の販売と流通で構成されます。抗生物質、インスリン、ワクチン、腫瘍治療薬など、様々な疾患や病状の治療に不可欠な薬剤を扱っています。注射剤は、救急医療から慢性疾患治療薬の日常投与まで、多様な用途に使用されています。病院や診療所で使用されるほか、自動注射器の進歩によりセルフケアの場面でも使用されるようになってきています。慢性疾患の負担の増加、プレフィルドやセルフ注射剤の使用の増加、がん治療のための安定したドラッグデリバリービークルの継続的な実践など、いくつかの要因が注射剤市場の開拓を後押ししています。しかし、市場は高い研究開発コスト、規制遵守コスト、厳しい条件下での複雑な製造プロセスなどの限界や課題に直面しています。その一方で、注射剤の急速な開発と承認、注射剤に関するメーカー間の戦略的提携により、新たな機会が生まれつつあります。さらに、ドラッグデリバリーの安全性、利便性、有効性を向上させることは、患者のコンプライアンスを高め、転帰を改善することにつながります。

主な市場の統計
基準年[2023] 5,633億米ドル
予測年[2024] 6,170億4,000万米ドル
予測年 [2030] 1兆885億5,000万米ドル
CAGR(%) 9.86%

薬剤クラス:細胞シグナル伝達のためのサイトカイン注射剤人気の高まり

血液凝固に不可欠な血液因子は、血友病やその他の血液凝固障害の治療や出血予防に用いられる注射剤です。血液因子はヒト血漿または遺伝子組換え技術によって得られます。血友病AおよびBは、これらの治療を必要とする最も一般的な疾患です。サイトカインは、免疫系における細胞シグナル伝達に重要な、注射可能なタンパク質の幅広いカテゴリーです。インターフェロン、インターロイキン、コロニー刺激因子などが含まれ、がんや自己免疫疾患の治療に使用されます。免疫グロブリンは、さまざまな免疫不全症候群や自己免疫疾患によく使用される、免疫系に不可欠な成分です。これらの薬剤は、免疫系が病原体と闘うために必要な抗体を提供します。インスリンは、血糖値の調節に不可欠なペプチドホルモンです。インスリンは主に糖尿病患者に投与され、体内で十分なインスリンが自然に分泌されない場合に使用されます。モノクローナル抗体(mAbs)は、有害な病原体を撃退する免疫系の能力を模倣した人工分子です。これらの薬は、がん、自己免疫疾患、感染症など、さまざまな症状の治療に変化をもたらしています。ペプチドホルモンには、成長ホルモン、糖尿病治療薬のグルカゴン様ペプチド-1(GLP-1)作動薬、カルシトニンなど、インスリン以外のさまざまな注射ホルモンが含まれます。これらのホルモンは、成長、グルコース代謝、骨のホメオスタシスの調節など、様々な役割を果たしています。

用途:自己免疫疾患の治療における注射剤の応用拡大

自己免疫疾患の注射剤は、関節リウマチ、多発性硬化症、クローン病など様々な疾患を治療します。注射剤のサブクラスである生物学的製剤は、免疫系を調節する標的アプローチにより、しばしば処方されます。注射剤が好まれるのは、その作用発現の速さと経口薬よりも高い有効性のためです。心血管系疾患に対する注射剤は、心不全、不整脈、高血圧などの状態を管理することを目的としています。これらの注射は、抗凝固剤や凝固因子などの治療が遅れると致命的な事態を招く可能性がある場合に、迅速な処置を提供するもので、緊急の場面ではしばしば重要な役割を果たします。感染症では、抗ウイルス薬、抗生物質、抗真菌薬、特に高血中濃度を迅速に必要とする場合や経口投与が不可能な場合に、注射剤は極めて重要です。特に、高濃度の血中濃度を迅速に必要とする場合や、経口投与が不可能な場合には、抗ウイルス剤、抗生物質、抗真菌剤にとって欠かせないものとなっています。神経注射剤は、アルツハイマー病、多発性硬化症、片頭痛などの疾患を治療します。モノクローナル抗体は血液脳関門を通過する能力があるため、この分野で重要です。がん領域の注射剤には、化学療法剤、ホルモン療法剤、免疫療法剤などがあり、さまざまながんの治療に不可欠です。注射剤が好まれるのは、高い局所濃度を達成し、消化管吸収の問題を回避する必要があるためです。オピオイドや非ステロイド性抗炎症薬(NSAIDs)といった疼痛管理用の注射剤は、急性、慢性、術後の疼痛管理において、その速さと有効性から好まれています。注射剤のアプリケーションセグメントを比較すると、それぞれがヘルスケア領域で明確なニーズに応えていることがわかります。自己免疫疾患は長期的な治療レジメンを必要とし、注射剤が持続的な緩和をもたらします。対照的に、心血管系の注射剤は緊急性が高く、迅速な生理学的反応が要求されることが多いです。感染症の注射剤は、感染症を効果的に抑制するために、広域かつ迅速に作用するものでなければなりません。神経領域では、血液脳関門の問題を考慮すると、注射剤は標的を絞って投与できるという利点があります。がん治療薬の注射剤は、腫瘍部位での高濃度投与による標的治療の利点を提供します。最後に、注射剤による疼痛管理は、経口薬ではしばしば達成不可能な急性の激痛を即座に緩和します。

地域別の洞察

南北アメリカ、特に米国とカナダでは、糖尿病やがんなどの疾患の蔓延により、注射剤に対する需要が高いです。高度なヘルスケアインフラと一人当たり医療費の高さが、新しい注射技術の革新と採用を後押ししています。これらの市場では、薬剤の有効性、安全性、使いやすさが顧客の購買行動に影響を与えています。南米の注射剤市場は、ブラジル、アルゼンチン、チリなどの国々におけるヘルスケア施設の改善、経済的安定性の向上、ヘルスケア改革に対する政府の支援により、着実に成長しています。欧州は、医療制度が整備され、償還政策も好意的で、注射剤市場が新興国市場として発展しています。東欧諸国では、先進的な治療薬へのアクセスが向上しているため、成長率が加速しています。サウジアラビアやアラブ首長国連邦などの中東は、ヘルスケア・インフラが整備され、民間セクターの投資が増加しているため、有望な市場です。一方、アフリカでは注射剤療法の導入が進んでいますが、医薬品の購入価格や医薬品へのアクセスに関する課題に直面しています。アジア太平洋地域は、経済成長、ヘルスケアセクターの拡大、バイオ医薬品研究への投資の増加により、注射剤の急成長市場として浮上しています。中国、インド、日本などの国々が最前線で、ジェネリック医薬品と革新的な注射剤の両方に対する需要が高いです。中国では、国内製造と外資導入が盛んで、広大な国内市場に対応しています。日本は技術の進歩で知られ、次世代注射剤を含む医薬品の研究開発に多額の投資を行っています。製薬産業が急成長しているインドは、注射剤にとって大きな市場です。低コストの製造と中間層の増加は、より手頃な注射薬の選択肢を求める購買行動に好影響を与えます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは注射剤市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、注射剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.注射剤市場の市場規模および予測は?

2.注射剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.注射剤市場の技術動向と規制枠組みは?

4.注射剤市場における主要ベンダーの市場シェアは?

5.注射剤市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患の負担増大
      • プレフィルド薬剤と自己注射薬剤の使用増加
      • がん治療における制御ドラッグデリバリー媒体の継続的な実践
    • 抑制要因
      • 製品リコールの発生件数の増加
    • 機会
      • 注射剤の急速な開発と承認
      • 注射剤のメーカー間の戦略的提携
    • 課題
      • 複雑な製造工程と注射剤の不足
  • 市場セグメンテーション分析
    • 薬剤クラス:細胞シグナル伝達のためのサイトカイン注射用タンパク質の人気増加
    • 応用:自己免疫疾患の治療における注射剤の応用が拡大
  • 市場動向分析
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制枠組みの分析
  • 顧客のカスタマイズ

第6章 注射剤市場:分子タイプ別

  • 巨大分子
  • 小分子

第7章 注射剤市場:薬剤クラス別

  • 血液因子
  • サイトカイン
  • 免疫グロブリン
  • インスリン
  • モノクローナル抗体
  • ペプチドホルモン

第8章 注射剤市場:注射経路別

  • 筋肉内
  • 眼内
  • 脊髄内
  • 静脈内
  • 皮下

第9章 注射剤市場:用途別

  • 自己免疫疾患
  • 心血管疾患
  • 感染症
  • 神経学
  • 腫瘍学
  • 痛み

第10章 南北アメリカの注射剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の注射剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの注射剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析(2023年)
  • FPNVポジショニングマトリックス(2023年)
  • 競合シナリオ分析
    • Sun PharmaとTaroが合併契約を発表
    • Glenmarkは人気の抗糖尿病薬リラグルチドのバイオシミラーをインドで発売
    • Bristol Myersのオプジーボ注射剤が腎臓がんの臨床試験で主要目標を達成

第14章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INJECTABLE DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 118. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 126. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 128. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 136. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 137. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 142. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 150. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 158. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 166. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 182. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 190. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 198. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 232. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 240. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 248. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 256. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 264. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 272. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 274. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 275. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 280. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 288. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 296. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 304. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 306. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 307. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 308. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 312. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 313. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 314. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 315. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 320. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 321. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 322. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 323. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 324. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 328. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 330. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 336. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 338. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 344. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 345. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 346. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 347. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 348. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 352. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 353. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 354. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 355. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 356. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 357. SWITZERLAND INJECTABLE D
目次
Product Code: MRR-742BD517FCA4

[199 Pages Report] The Injectable Drugs Market size was estimated at USD 563.30 billion in 2023 and expected to reach USD 617.04 billion in 2024, at a CAGR 9.86% to reach USD 1,088.55 billion by 2030.

The injectable drugs market comprises sales and distribution of medications and therapies that are administered through intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection routes. The market caters to various drugs, including antibiotics, insulin, vaccines, and oncology treatments, that are integral in treating multiple diseases and medical conditions. Injectable drugs have diverse applications ranging from emergency care to routine administration of chronic disease medications. They are used in hospitals, clinics, and, increasingly, self-care settings due to advancements in auto-injection devices. Several factors, such as the rising burden of chronic diseases, the growing use of prefilled and self-injectable drugs, and the ongoing practice of steady drug delivery vehicles for cancer treatment, drive the development of the injectable drugs market. However, the market faces limitations and challenges, including high research and development costs, regulatory compliance costs, and complex manufacturing processes under stringent conditions. On the other hand, new opportunities are emerging due to rapid developments and approvals in injectable drugs and strategic alliances among manufacturers for injectable drugs. Moreover, improving drug delivery methods' safety, convenience, and efficacy can lead to increased patient compliance and better outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 563.30 billion
Estimated Year [2024] USD 617.04 billion
Forecast Year [2030] USD 1,088.55 billion
CAGR (%) 9.86%

Drug Class: Increasing preference for cytokines injectable protein for cell signaling

Blood factors, essential for blood clotting, are injectable agents used to treat and prevent bleeding in individuals with hemophilia and other clotting disorders. They are derived either from human plasma or through recombinant technology. Hemophilia A and B are the most common disorders requiring these treatments. Cytokines are a broad category of injectable proteins critical in cell signaling within the immune system. They include interferons, interleukins, and colony-stimulating factors and are used in treating cancers and autoimmune conditions. Immunoglobulins are essential immune system components commonly used for various immunodeficiency syndromes and autoimmune diseases. These drugs provide necessary antibodies for the immune system to combat pathogens. Insulin is a peptide hormone vital for the regulation of blood glucose levels. It is primarily administered to individuals with diabetes when their body cannot produce sufficient insulin naturally. Monoclonal Antibodies (mAbs) are engineered molecules that imitate the immune system's capacity to fight off harmful pathogens. These drugs have transformed treatment across a spectrum of conditions, including cancer, autoimmune diseases, and infectious diseases. Peptide hormones encompass a variety of injectable hormones other than insulin, such as growth hormone, glucagon-like peptide-1 (GLP-1) agonists for diabetes, and calcitonin. They play various roles, including regulating growth, glucose metabolism, and bone homeostasis.

Application: Growing application of injectable drugs for treating autoimmune diseases

Injectable drugs for autoimmune diseases treat various conditions, including rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Biologics, a subclass of injectable drugs, are often prescribed due to their targeted approach to modulating the immune system. The need-based preference for injectables stems from their quick onset of action and higher efficacy than oral medications. Injectable drugs for cardiovascular diseases aim to manage conditions such as heart failure, arrhythmia, and hypertension. These injections are often critical in emergency settings, providing rapid action where delayed treatment, such as anticoagulants or clotting factors, can be fatal. For infectious diseases, injectable drugs are crucial for antivirals, antibiotics, and antifungals, especially when high blood concentrations are required quickly, or oral administration is not feasible. They are critical in hospital settings for severe or resistant infections. Neurology injectables treat disorders, including Alzheimer's, multiple sclerosis, and migraines. Monoclonal antibodies are significant in this segment for their ability to cross the blood-brain barrier. Oncology injectables include chemotherapy agents, hormonal therapies, and immunotherapies, essential for treating various cancers. The preference for injections comes from the need to achieve high local concentration and to bypass gastrointestinal absorption issues. Injectable drugs for pain management, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred in acute, chronic, and post-operative pain management for their speed and efficacy. In comparing the application segments for injectable drugs, it is apparent that each serves a distinct need in the healthcare sphere. Autoimmune diseases require long-term treatment regimens where injectables offer sustained relief. In contrast, cardiovascular injectable drugs are often emergency-related and demand rapid physiological responses. Infectious disease injectables must be broad-spectrum and rapidly acting to curb infections effectively. Neurology benefits from the targeted delivery achieved by injectables, a distinct advantage given the blood-brain barrier challenge. Injectable oncology drugs offer the benefit of targeted therapy with higher concentrations at the tumor site. Lastly, pain management with injectables provides immediate relief from acute and severe pain, which is often unattainable with oral medications.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a high demand for injectable drugs due to the prevalence of diseases such as diabetes and cancer. Advanced healthcare infrastructure and high per capita healthcare expenditure drive the innovation and adoption of new injection technologies. Drug efficacy, safety profiles, and ease of use influence customer purchasing behavior in these markets. South America's market for injectable drugs is growing steadily due to improving healthcare facilities, increasing economic stability, and governmental support for healthcare reforms in countries such as Brazil, Argentina, and Chile. Europe represents a developing injectable drug market with well-established healthcare systems and favorable reimbursement policies. Eastern European countries are experiencing faster growth rates due to increased accessibility to advanced therapeutics. The Middle East, with countries such as Saudi Arabia and the UAE, shows a promising injectable drugs market due to rising healthcare infrastructure and increasing private sector investments. Africa, on the other hand, is progressively adopting injectable drug therapies but faces challenges related to affordability and access to medicine. The APAC region is emerging as the fastest-growing market for injectable drugs, driven by economic growth, expanding healthcare sectors, and increasing investments in biopharmaceutical research. Countries such as China, India, and Japan are at the forefront, with a high demand for both generic and innovative injectable drugs. In China, local manufacturing and foreign investment are extensive, catering to a vast domestic market. Japan is known for its technological advancements and invests heavily in pharmaceutical R&D, including next-generation injectable treatments. With a burgeoning pharmaceutical industry, India offers a large market for injectable drugs. Low-cost manufacturing and a growing middle class impact purchasing behaviors favorably toward more affordable injectable options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Injectable Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Injectable Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Cipla Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., Eli Lilly and Company, EVER Neuro Pharma GmbH, F. Hoffmann-La Roche Ltd., Ferring B.V., Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., SCHOTT PHARMA AG & CO. KGAA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Molecule Type
    • Large Molecule
    • Small Molecule
  • Drug Class
    • Blood Factors
    • Cytokines
    • Immunoglobulin
    • Insulin
    • Monoclonal Antibodies
    • Peptide Hormone
  • Injection Routes
    • Intramuscular
    • Intraocular
    • Intrathecal
    • Intravenous
    • Subcutaneous
  • Application
    • Autoimmune Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurology
    • Oncology
    • Pain
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Injectable Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Injectable Drugs Market?

3. What are the technology trends and regulatory frameworks in the Injectable Drugs Market?

4. What is the market share of the leading vendors in the Injectable Drugs Market?

5. Which modes and strategic moves are suitable for entering the Injectable Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Burden of Chronic Diseases
      • 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
      • 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in Incidences of Product Recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
      • 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
    • 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulin
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intraocular
  • 8.4. Intrathecal
  • 8.5. Intravenous
  • 8.6. Subcutaneous

9. Injectable Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiovascular Diseases
  • 9.4. Infectious Diseases
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Pain

10. Americas Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sun Pharma and Taro announce merger agreement
    • 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
    • 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio